India’s Cumulative COVID-19 Vaccination Coverage crosses the landmark of 110 Cr

November 11, 2021
New Delhi, November 11, 2021:

With the administration of 57,54,817 vaccine doses in the last 24 hours, India’s COVID-19 vaccination coverage has crossed the landmark of 110 Cr (1,10,23,34,225) as per provisional reports till 7 am today.  This has been achieved through 1,12,38,854 sessions.

The break-up of the cumulative figureas per the provisional report till 7 am today include:

 

 

HCWs

1st Dose 1,03,79,922
2nd Dose 92,97,352
 

FLWs

1st Dose 1,83,73,373
2nd Dose 1,61,02,356
 

Age Group 18-44 years

1st Dose 42,81,52,713
2nd Dose 16,02,59,021
 

Age Group 45-59 years

1st Dose 17,72,47,072
2nd Dose 10,18,78,442
 

Over 60 years

1st Dose 11,11,04,883
2nd Dose 6,95,39,091
Total 1,10,23,34,225

 

The recovery of 13,878 patients in the last 24 hours has increased the cumulative tally of recovered patients (since the beginning of the pandemic) to 3,38,00,925.

Consequently, India’s recovery rate stands at 98.25%.

Sustained and collaborative efforts by the Centre and the States/UTs continue the trend of less than 50,000 Daily New Cases that is being reported for 137 consecutive days now.

13,091 new cases were reported in the last 24 hours.

The Active Caseload is presently at 1,38,556 is lowest in 266 days. Active cases presently constitute 0.40% of the country’s total Positive Cases, which is lowest since March 2020.

The testing capacity across the country continues to be expanded. The last 24 hours saw a total of

11,89,470tests being conducted. India has so far conducted over 61.99 Cr (61,99,02,064) cumulative tests.

While testing capacity has been enhanced across the country, Weekly Positivity Rate at 1.18% remains less than 2% for the last 48 days now. The Daily Positivity rate reported to be1.10%. The daily Positivity rate has remained below 2% for last 38 days and below 3% for 73 consecutive days now.

healthysoch

Stay informed with the latest news from HealthySoch. Sign up today for exclusive insights and updates!

We promise we never spam!

Leave a Reply

Your email address will not be published.

Columnists

HealthySoch

Don't Miss

Bharat Biotech Concludes Final Analysis for COVAXIN® Efficacy from Phase 3 Clinical Trials

“Efficacy analysis demonstrates COVAXIN® to be 77.8% effective against symptomatic

COVID-19 in children is often asymptomatic

COVID19: Myth vs. Facts : COVID-19 in children is often